摘要
目的探讨三维适形放射治疗技术（3-DCRT）治疗肝癌的有效性和安全性。方法对86例原发性肝癌患者应用三维适形放射治疗，其中男性患者64例，女性22例，单次剂量3-4Gy，每周3-4次，DT36-60Gy。结果86例中可评价疗效的有81例，获CR4例，PR38例，NC21例，PD18例。RR为51.9%（42/81），DCR为77.8%（63/81），1年生存率为53.1%（43/81）。AFP值下降者31例，下降率为68.9%（31/45）其中下降1/2以上者20例。毒副作用主要为近期胃肠道反应，经对症处理恢复正常。13例患者出现Ⅰ-Ⅱ度白细胞下降，发生率为16.1%（13/81）。8例患者出现Ⅰ度血小板下降，发生率为9.9%（8/81）。放疗中肝脏急性不良反应1级7例，发生率为8.6%（7/81），经积极护肝治疗恢复正常。2例乙型肝炎合并有肝硬化患者，分别于放疗结束2个月及6个月时发生严重的肝脏损害。结论三维适形放射治疗原发性肝癌疗效好，毒副作用轻，但应该严格掌握其治疗的适应证。
Objective To evaluate the efficacy and safety of 3-dimensional conformal radiation therapy（3-DCRT）in the treatment of primary hepatocellu carcinoma. Methods 86 patients with primary hepatocellu carcinoma were enrolled,including 64male and 22 female patients. The median age was 55 （ range,22 to 75） years old. The patients were irradiated at 3-4Gy per fraction, 3 -5 fractions per week to a total dose of 36-60Gy . Results 81 patients were evaluable for response, in which 4 achieved complete response （CR） and 38 partial responses （PR）, so the RR was 51.9%. 21 patients had no change（NC） and 18 progressive diseases（PD）. The One-year survival rate was 53.1%. The major acute toxicities were reversible bone marrow suppression and gastrointestinal tract side reaction. 7 patients developed Grade 1 acute liver toxicity. 2 patient with hepatitis B developed severe liver function impairment. Conclusion The results of 3-DCRT for primary hepatocellu carcinoma were encouraging with mild toxicities.
出处
《实用癌症杂志》
2007年第4期373-375,共3页
The Practical Journal of Cancer
关键词
原发性肝癌
放射治疗
三维适形放射治疗
Primary hepatocellu carcinoma
Radiotherapy
Three-dimensional conformal radiotherapy（3-DCRT）
